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Abstract
A low arousal threshold is believed to predispose to breathing instability during sleep. The present
authors hypothesised that trazodone, a nonmyorelaxant sleep-promoting agent, would increase the
effort-related arousal threshold in obstructive sleep apnoea (OSA) patients.
In total, nine OSA patients, mean±SD age 49±9 yrs, apnoea/hypopnoea index 52±32 events·h-1, were
studied on 2 nights, one with trazodone at 100 mg and one with a placebo, in a double blind
randomised fashion. While receiving continuous positive airway pressure (CPAP), repeated arousals
were induced: 1) by increasing inspired CO2 and 2) by stepwise decreases in CPAP level. Respiratory
effort was measured with an oesophageal balloon. End-tidal CO2 tension (PET,CO2) was monitored
with a nasal catheter.
During trazodone nights, compared with placebo nights, the arousals occurred at a higher
PET,CO2 level (mean±SD 7.30±0.57 versus 6.62±0.64 kPa (54.9±4.3 versus 49.8±4.8 mmHg),
respectively). When arousals were triggered by increasing inspired CO2 level, the maximal
oesophageal pressure swing was greater (19.4±4.0 versus 13.1±4.9 cmH2O) and the oesophageal
pressure nadir before the arousals was lower (-5.1±4.7 versus -0.38±4.2 cmH2O) with trazodone.
When arousals were induced by stepwise CPAP drops, the maximal oesophageal pressure swings
before the arousals did not differ.
Trazodone at 100 mg increased the effort-related arousal threshold in response to hypercapnia in
obstructive sleep apnoea patients and allowed them to tolerate higher CO2 levels.
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Obstructive sleep apnoea (OSA) syndrome is a common disorder occurring in at least 4% of
middle-aged males and 2% of females [1]. It is characterised by repetitive pharyngeal collapse
during sleep, leading to sleep disruption, arousals and nocturnal arterial oxygen desaturation.
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Apnoeas and hypopnoeas typically end with an arousal. Arousal from sleep is, therefore,
believed to be an important mechanism for re-establishing airway patency in OSA. However,
a recent study by YOUNES [2] demonstrated that the airway opening can precede arousal and that
there may be no arousal at the end of a respiratory event in some cases. This finding suggests
that an arousal is not always needed to restore flow after an apnoea or a hypopnoea. YOUNES [2]
also demonstrated that the occurrence of an arousal at upper airway opening (the end of the
apnoea) is associated with a greater ventilatory overshoot and a greater subsequent undershoot,
which may promote further breathing instability. This observation suggests that arousals may
contribute to sleep apnoea severity.
Based on this concept, some authors have tried to treat sleep apnoea patients by increasing the
arousal threshold with sedatives, such as benzodiazepines, without much success [3]. This
failure may be due to a myorelaxant effect of benzodiazepine on upper airway dilator muscles.
Trazodone is an antidepressant medication approved by the US Food and Drug Administration
in 1982. It appears to work by increasing brain levels of serotonin (5-hydroxytryptamine) but
is chemically unrelated to the selective serotonin reuptake inhibitors, the tri-cyclic
antidepressants (TCAs) or the monoamine oxidase inhibitors. Trazodone is also one of the
most widely used sleep-promoting agents in the USA. The present authors hypothesised that
trazodone would increase the arousal threshold based on its hypnotic properties. However,
unlike benzodiazepines, it should not decrease upper airway muscle activity, as serotonin, and
specifically trazodone, has been shown to be a stimulant of upper airway muscle activity in an
English bulldog model of sleep apnoea [4].
In normal subjects, arousal from nonrapid eye movement (NREM) sleep, secondary to
hypoxaemia, without airway occlusion, whether isocapnic [5] or hypocapnic [6], is surprisingly
inconsistent. Hypercapnia is generally a more potent arousal stimulus than hypoxaemia [7].
Studies of hyperoxic hypercapnia have found that arousal tends to occur when the end-tidal
CO2 tension (PET,CO2) reaches 1.3–2.0 kPa (10–15 mmHg) above the baseline waking level
[8]. In sleep apnoea patients, the mechanisms whereby apnoeas lead to arousal are not
completely clear. Apnoeas are characterised by worsening hypoxaemia and hypercapnia in
association with a progressive increase in respiratory effort. Although hypercapnia and
hypoxaemia occur during each apnoea, healthy subjects usually arouse at a specific level of
negative intrathoracic pressure, suggesting that respiratory effort is the main stimulus to arousal
[9]. However, because hypercapnia without respiratory effort has been reported to induce
arousals [8], an independent role of hypercapnia cannot be ruled out. The present authors,
therefore, sought to determine whether trazodone could increase the stimulus required to induce
arousal from both increased inspired CO2 and progressive upper airway collapse (stepwise
continuous positive airway pressure (CPAP) drops). Some of the results of the present study
have been reported previously [10].
MATERIAL AND METHODS
Study subjects
In total, 10 subjects with moderate-to-severe OSA determined by overnight polysomnography,
who were treated with CPAP, were enrolled in the study. Subjects with any medical problems
affecting the upper airway (other than OSA), or taking any drug having an interaction with
trazodone were excluded from the study. Considering the results of GLEESON et al. [9], who
reported that their subjects aroused at a mean±SD oesophageal pressure of -14.7±2.4 cmH2O,
it was calculated that at least seven subjects were needed, in order to have 80% power to detect
a 4±3 cmH2O difference in oesophageal pressure swings (respiratory effort) between trazodone
and placebo, using a paired t-test with α=0.05. For the CO2 level before arousal, at least six
patients were needed, to have 80% power to detect a 0.40±0.27 kPa (3±2 mmHg) difference
between trazodone and placebo, using a paired t-test with α=0.05.
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Study design
Subjects were studied on 2 nights under two different conditions, placebo or trazodone 100 mg
(taken orally, 90 min before bedtime), in a randomised (blocks of four) double blind crossover
fashion. All data were analysed before the code of the randomisation was revealed. The placebo
pills were produced by the hospital pharmacy and were indistinguishable from the trazodone
tablets.
Methods
For the night studies, subjects reported to the Clinical Research Center (Beth Israel Deaconess
Medical Center, Boston, MA, USA) at 20:00 h, having been without food intake for at least 4
h. Paste-on electrodes were applied to the scalp, chin, chest and face to record the
electroencephalogram (EEG), electro-myogram, electro-oculogram and electrocardiogram.
Nostrils were decongested with oxymetazoline hydrochloride, and one nostril was
anaesthetised with 4% lidocaine (1–1.5 mL). A 10-cm deflated latex balloon linked with a
pressure catheter was inserted through the decongested, anaesthetised nostril and the tip of the
catheter was located at the distal third of the oesophagus. Once in place, the balloon was
partially inflated with 0.5 mL of air and connected to a calibrated pressure transducer. A mask
was placed over the subject’s nose and held in place with straps. A catheter was placed in front
of the free nostril to measure PET,CO2 (Capnograph/Oximeter Monitor; BCI, Waukesha, WI,
USA). A pulse oximeter was used to monitor blood oxygen saturation.
The subjects were allowed to fall asleep with CPAP in place at their usual level. If needed, the
CPAP level was titrated to eliminate any respiratory events or flow limitation. Once stable
stage 2 NREM sleep was observed, CO2 was administered through the inspiratory line of the
breathing apparatus. The CO2 level was gradually increased until the subject aroused from
sleep (fig. 1). This procedure was repeated 10 times consecutively. The maximal PET,CO2 the
subjects could tolerate before they arose, as well as the oesophageal pressure just before the
arousal, was recorded. An arousal was defined as an abrupt shift in EEG frequency which
included the theta-alpha pattern and/or a frequency >16 Hz (but not spindles) of ≥3 s duration.
During each night study, the CPAP level was also lowered in incremental steps of 3 cmH2O.
If the subject did not have an arousal for 1 min, the next 3-cmH2O decremental step was
performed. This was continued until the subject arose from sleep (fig. 2). The nadir oesophageal
pressure and the maximal oesophageal pressure swings just prior to arousal were recorded.
This procedure was repeated 10 times.
Analysis
Data were reported as mean±SD. All data were analysed before the randomisation code was
released. The same blinded investigator scored the arousals in all the recordings. To assess the
maximal respiratory effort before the arousal, both the maximal oesophageal pressure swings
(mean of the last three inspiratory efforts before the arousals) and the oesophageal pressure
nadir before the arousals were determined. To compare the respiratory effort and PET,CO2
prior to arousal between placebo and trazodone, a paired t-test was used, as each subject was
his/her own control.
RESULTS
Of the 10 subjects enrolled, one could not complete the protocol because she felt weak and
light-headed about 30 min after taking trazodone 100 mg (randomisation code was broken for
this patient). Therefore, the results of the other nine patients are reported. Demographic data
are reported in table 1. During trazodone nights compared with placebo nights, the arousals
occurred at a higher PET,CO2 level (mean±SD 7.30±0.57 versus 6.62±0.64 kPa (54.9±4.3
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versus 49.8±4.8 mmHg), respectively; p=0.038). When arousals were triggered by increasing
inspired CO2 level, the maximal oesophageal pressure swings (mean of the last three
inspiratory efforts before the arousals) were greater (19.4±4.0 versus 13.1±4.9 cmH2O;
p=0.002; fig. 3) and the oesophageal pressure nadir before the arousals was lower with
trazodone (-5.1±4.7 versus -0.38±4.2 cmH2O; p=0.02; note that patients were receiving
CPAP). However, when arousals were induced by stepwise CPAP drops, the maximal
oesophageal pressure swings before arousal did not differ between trazodone and placebo (16.9
±6.3 versus 15.5±6.9 cmH2O; p=0.39; fig. 3). The difference in the oesophageal pressure nadir
was also nonsignificant (-6.0±8.2 versus -5.0±9.7 cmH2O; p=0.53).
DISCUSSION
The main finding of the present study was that, in OSA patients, trazodone increased the
respiratory effort-related arousal threshold in response to hypercapnia and allowed these
individuals to tolerate a higher CO2 level without arousal. The current authors speculate that,
in some OSA patients without a highly compromised upper airway, a low arousal threshold
could contribute to the severity of their disease and a medication like trazodone might reduce
apnoea severity. Conversely, in patients with a highly compromised pharyngeal airway, airflow
resistance increases markedly during sleep and complete obstruction of the upper airway is
common. In these patients, an increase in the arousal threshold would probably only extend
the duration of the apnoea as an arousal will most likely be required to reopen the collapsed
upper airway.
When an individual without a major anatomical airway problem falls asleep, the sleep-induced
fall in upper airway dilator muscles may generate only a mild increment in resistance, which
will result in a hypopnoea. Over time, the O2 tension falls, CO2 tension rises and ventilatory
effort increases. Eventually one of two events must occur. On the one hand, the pharyngeal
dilator muscles could be recruited adequately before the arousal occurs, thereby allowing
sufficient ventilation for sleep to be maintained. On the other hand, an arousal could occur,
accompanied by an abrupt increase in ventilation (overshoot), which would induce a
subsequent apnoea or hypopnoea when the individual returns to sleep. In this second situation,
if an arousal occurs each time there is a mild increase in upper airway resistance, the individual
will wax and wane between sleep and wake with cycling respiratory events. Depending on the
prevailing mechanics of the pharyngeal airway, either central or obstructive apnoea could result
[11]. However, if one could increase the arousal threshold with a medication such as trazodone,
the patient could potentially stay asleep long enough to recruit upper airway dilator muscles
and reopen the upper airway without arousal [12]. In other words, an increase in arousal
threshold in OSA patients with otherwise effective compensatory mechanisms during sleep
could stabilise ventilation without arousal, at least in theory.
Other drugs have been used to treat OSA in the past. TCA medications, such as protriptyline,
have been shown to increase hypoglossal nerve activity in cats [13]. However, this drug had
only a modest effect on OSA in humans, which was probably mediated through suppression
of rapid eye movement sleep [14,15]. Benzodiazepines tend to decrease hypoglossal nerve
activity in cats [13], as well as the tongue muscle in humans [16], but some positive effects
have been reported in humans with central sleep apnoea [17]. BERRY et al. [3] have tried using a
benzodiazepine (triazolam) to treat OSA patients. Although they did observe an increase in the
arousal threshold, the apnoea/hypopnoea index did not decrease and the duration of the
respiratory events mildly increased [3]. This negative result may be due to the lack of selection
of OSA patients without a highly compromised upper airway. As mentioned previously,
increasing the arousal threshold will certainly not help OSA patients with a highly collapsible
upper airway, as they will probably need an arousal to restore pharyngeal patency. Moreover,
benzodiazepines have a myorelaxant effect, which can decrease upper airway dilator muscle
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activity. Trazodone, at least in theory, has the opposite effect on the upper airway musculature
because of its central serotoninergic effect, as suggested by VEASEY et al. [18]. Other drugs with
serotoninergic activity, such as fluoxetine, mirtazapine and paroxetine, have been tested with
some success in animals, although only limited success has been reported in humans,
potentially due to minimal effects on the arousal threshold [15,19–23].
There may be other reasons why suppression of arousal will not improve apnoea severity. Low
upper airway dilator muscle “responsiveness” to CO2 during sleep may prevent an adequate
response of pharyngeal muscles during an apnoea or hypopnoea, even if CO2 levels rise
substantially. Marked instability in ventilatory control (high loop gain) or high ventilatory
response to arousal [24] may also contribute to OSA severity, by inducing an excessive
ventilatory response to a mild respiratory disturbance and promoting cyclic breathing [25].
Thus, suppression of arousal with drugs, such as trazodone, is not likely to help all OSA
patients.
As there was such a clear effect of trazodone on the CO2-induced arousal threshold, the present
authors were surprised by the lack of a significant effect on the arousal threshold in response
to a stepwise decrease in CPAP. When the CPAP level was dropped, some patients may have
been aroused by the facial pressure difference or startle arousals more than by the increase in
upper airway resistance. Another possibility is that trazodone is affecting arousal response to
chemical stimuli (i.e. CO2) but not mechanical stimuli; however, if this were true it would
challenge the notion that individuals awake at a specific oesophageal pressure, regardless of
the stimulus (hypoxia, loading, hypercapnia) [9].
The main limitation of the present study is that the effect of trazodone was tested in artificial
conditions (by increasing CO2 and decreasing CPAP level) and not during “natural” apnoea
and hypopnoeas during sleep. Therefore, the effect of trazodone in clinical OSA is only
speculative. These standardised conditions were, however, required for precise comparison of
respiratory efforts between trazodone and placebo. The hypothesis of a beneficial effect of
trazodone in a subset of OSA patients, with a mildly compromised upper airway and the ability
to recruit muscles, will, therefore, have to be tested in future clinical trials. The best way to
determine which patients may respond to an increase in arousal threshold also remains unclear
at the current time. Another limitation of the present study is the relatively small sample size.
However, it should be emphasised that the sample size was determined based on rigorous power
calculations as described, and that the present results are quite consistent for each participant,
making a spurious result unlikely.
In conclusion, trazodone increased the respiratory effort-related arousal threshold in response
to hypercapnia in obstructive sleep apnoea patients and allowed them to tolerate a higher
CO2 level. The arousal threshold induced by decrementing levels of continuous positive airway
pressure was not altered by trazodone. The effect of trazodone on arousal threshold might open
new treatment opportunities in the future, for a subset of obstructive sleep apnoea patients.
Acknowledgments
SUPPORT STATEMENT This work was supported by the National Institutes of Health (NIH), grants HL48531 and
HL60292, NIH/National Heart, Lung, and Blood Institute grant T32 HL007901, and NIH/RR01032. Support was also
received from the Fond National Suisse de la Recherche Scientifique (Bern, Switzerland), the Fondation SICPA
(Lausanne, Switzerland) and the Société Académique Vaudoise (Lausanne).
REFERENCES
1. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered
breathing among middle-aged adults. N Engl J Med 1993;328:1230–1235. [PubMed: 8464434]
Heinzer et al. Page 5
Eur Respir J. Author manuscript; available in PMC 2009 August 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
2. Younes M. Contributions of upper airway mechanics and control mechanisms to severity of obstructive
apnea. Am J Respir Crit Care Med 2003;168:645–658. [PubMed: 12773321]
3. Berry RB, McCasland CR, Light RW. The effect of triazolam on the arousal response to airway
occlusion during sleep in normal subjects. Am Rev Respir Dis 1992;146:1256–1260. [PubMed:
1443881]
4. Veasey SC, Panckeri KA, Hoffman EA, Pack AI, Hendricks JC. The effects of serotonin antagonists
in an animal model of sleep-disordered breathing. Am J Respir Crit Care Med 1996;153:776–786.
[PubMed: 8564132]
5. Douglas NJ, White DP, Weil JV, et al. Hypoxic ventilatory response decreases during sleep in normal
men. Am Rev Respir Dis 1982;125:286–289. [PubMed: 7065538]
6. Gothe B, Goldman MD, Cherniack NS, Mantey P. Effect of progressive hypoxia on breathing during
sleep. Am Rev Respir Dis 1982;126:97–102. [PubMed: 7091916]
7. Berthon-Jones M, Sullivan CE. Ventilation and arousal responses to hypercapnia in normal sleeping
humans. J Appl Physiol 1984;57:59–67. [PubMed: 6432751]
8. Ayas NT, Brown R, Shea SA. Hypercapnia can induce arousal from sleep in the absence of altered
respiratory mechanoreception. Am J Respir Crit Care Med 2000;162:1004–1008. [PubMed:
10988121]
9. Gleeson K, Zwillich CW, White DP. The influence of increasing ventilatory effort on arousal from
sleep. Am Rev Respir Dis 1990;142:295–300. [PubMed: 2382892]
10. Heinzer RC, White DP, Jordan AS, Lo YL, Dover L, Schory K, Malhotra A. Trazodone increases
arousal threshold in obstructive sleep apnea. Proc Am Thorac Soc 2006;3:A316.
11. Malhotra A, Jordan AS. Did fat boy Joe need hormone replacement? Sleep 2006;29:16–18. [PubMed:
16453975]
12. Stanchina ML, Malhotra A, Fogel RB, et al. Genioglossus muscle responsiveness to chemical and
mechanical stimuli during non-rapid eye movement sleep. Am J Respir Crit Care Med 2002;165:945–
949. [PubMed: 11934719]
13. Bonora M, John WM, Bledsoe TA. Differential elevation by protriptyline and depression by diazepam
of upper airway respiratory motor activity. Am Rev Respir Dis 1985;131:41–45. [PubMed: 3966713]
14. Smith PL, Haponik EF, Allen RP, Bleecker ER. The effects of protriptyline in sleep-disordered
breathing. Am Rev Respir Dis 1983;127:8–13. [PubMed: 6849555]
15. Hanzel DA, Proia NG, Hudgel DW. Response of obstructive sleep apnea to fluoxetine and
protriptyline. Chest 1991;100:416–421. [PubMed: 1864117]
16. Drummond GB. Comparison of sedation with midazolam and ketamine: effects on airway muscle
activity. Br J Anaesth 1996;76:663–667. [PubMed: 8688266]
17. Guilleminault C, Crowe C, Quera-Salva MA, Miles L, Partinen M. Periodic leg movement, sleep
fragmentation and central sleep apnoea in two cases: reduction with Clonazepam. Eur Respir J
1988;1:762–765. [PubMed: 3234522]
18. Veasey SC, Fenik P, Panckeri K, Pack AI, Hendricks JC. The effects of trazodone with L-tryptophan
on sleep-disordered breathing in the English bulldog. Am J Respir Crit Care Med 1999;160:1659–
1667. [PubMed: 10556137]
19. Carley DW, Radulovacki M. M. Mirtazapine. a mixed-profile serotonin agonist/antagonist,
suppresses sleep apnea in the rat. Am J Respir Crit Care Med 1999;160:1824–1829. [PubMed:
10588592]
20. Castillo JL, Menendez P, Segovia L, Guilleminault C. Effectiveness of mirtazapine in the treatment
of sleep apnea/hypopnea syndrome (SAHS). Sleep Med 2004;5:507–508. [PubMed: 15341898]
21. Berry RB, Yamaura EM, Gill K, Reist C. Acute effects of paroxetine on genioglossus activity in
obstructive sleep apnea. Sleep 1999;22:1087–1092. [PubMed: 10617169]
22. Veasey SC. Serotonin agonists and antagonists in obstructive sleep apnea: therapeutic potential. Am
J Respir Med 2003;2:21–29. [PubMed: 14720019]
23. Carley DW, Olopade C, Ruigt GS, Radulovacki M. Efficacy of mirtazapine in obstructive sleep apnea
syndrome. Sleep 2007;30:35–41. [PubMed: 17310863]
Heinzer et al. Page 6
Eur Respir J. Author manuscript; available in PMC 2009 August 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
24. Jordan AS, McEvoy RD, Edwards JK, et al. The influence of gender and upper airway resistance on
the ventilatory response to arousal in obstructive sleep apnoea in humans. J Physiol 2004;558:993–
1004. [PubMed: 15218069]
25. Wellman A, Jordan AS, Malhotra A, et al. Ventilatory control and airway anatomy in obstructive
sleep apnea. Am J Respir Crit Care Med 2004;170:1225–1232. [PubMed: 15317668]
Heinzer et al. Page 7
Eur Respir J. Author manuscript; available in PMC 2009 August 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
FIGURE 1.
Example of an arousal induced by an increase in CO2. a) General view and b) increased
magnification of 30 s during an arousal. EMG: electro-myogram; EEG: electroencephalogram
(tracings O2-A1 and C3-A2); CPAP: continuous positive airway pressure; Poes: oesophageal
pressure; PET,CO2: end-tidal CO2 tension. .....: PET,CO2 level. #: arousal; ¶: respiratory effort.
1 mmHg=0.133 kPa.
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FIGURE 2.
Stepwise continuous positive airway pressure (CPAP) level drops. Poes: oesophageal pressure.
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FIGURE 3.
With trazodone, compared with placebo, subjects could tolerate higher respiratory effort before
arousal when a) the arousal was induced by increased CO2 levels, but not when b) it was induced
by continuous positive airway pressure drops. Poes: oesophageal pressure.
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TABLE 1
Demographic data of the study subjects
Age yrs 49.9±9.5 (37–64)
AHI events·h-1 52±32 (24–99)
BMI kg·m-2 31.2±4.5 (24.7–36.8)
Male/female n 6/3
Data are presented as mean±SD (range), unless otherwise stated. AHI: apnoea/hypopnoea index; BMI: body mass index.
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